The Antifungal and Anti-Pneumocystis Activities of the Novel Compound A3IS (Mycosinate).

Wiederhold, Nathan P; Patterson, Thomas F; Rebholz, Sandra; Boal, Connell W C; Ehrensberger, Monika; Boyle, Ryan; Cushion, Melanie T

Wiederhold, Nathan P; Patterson, Thomas F; Rebholz, Sandra; Boal, Connell W C; Ehrensberger, Monika; Boyle, Ryan; Cushion, Melanie T.

Affiliation

Wiederhold NP; Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center, San Antonio, Texas, USA.
Patterson TF; Department of Medicine, The University of Texas Health Science Center, San Antonio, Texas, USA.
Rebholz S; South Texas Veterans Health Care System, San Antonio, Texas, USA.
Boal CWC; Department of Internal Medicine, University of Cincinnatigrid.24827.3b College of Medicine, Cincinnati, Ohio, USA.
Ehrensberger M; Medical Research Service, Cincinnati Veterans Affairs Medical Center, Cincinnati, Ohio, USA.
Boyle R; Nektr Technologies Ltd., Finisklin Business Park, Sligo, Ireland.
Cushion MT; Nektr Technologies Ltd., Finisklin Business Park, Sligo, Ireland.

Antimicrob Agents Chemother ; 66(8): e0052122, 2022 08 16.

Article de En | MEDLINE | ID: mdl-35852368

Sujet(s)
Mots clés

antifungal susceptibility testing

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Pneumocystis / Pneumonie à Pneumocystis Limites: Humans Langue: En Journal: Antimicrob Agents Chemother Année: 2022 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google